ArticlePain research & management2026
Short-Chain Fatty Acids as Potential Mediators of NSAIDs' Effects on Arthritis Pain Relief.
Article in Pain research & management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Short-Chain Fatty Acids as Potential Mediators of NSAIDs' Effects on Arthritis Pain Relief.Pain research & management · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundNonsteroidal anti-inflammatory drugs (NSAIDs) are the preeminent choice for treating osteoarthritis (OA) and have demonstrated the ability to regulate the gut microbiome. This study aims to explore the possibility that pharmacologically modified microbiome plays a role in improvement of arthritis.
methodRats with the right knee joint subjected to anterior cruciate ligament transection (ACLT) surgery were randomly allocated to eight groups. Four weeks after the procedure, the rats were given an intervention with saline (NS), celecoxib (CE), diclofenac (DF), and tramadol (TM). The rats were executed after 6 weeks of intervention, serum was used to evaluate the levels of inflammation and pain-related factors (IL-1β, IL-6, TNF-α, LPS, CGRP, and NGF), rat joints were used to assess local inflammation in the joints (MyD88) and the effect of the drug on the cartilage (Micro CT, Safranin O-Fast Green stain), Von Frey fibrous filaments were used to assess the sensation of pain in rats, and the differences in feces for the gut microbiome and short-chain fatty acids (SCFAs) were compared by 16S rRNA sequencing and gas chromatographic analyses.
resultRats treated with CE, DF, and TM experienced significant relief from joint pain, but the analgesic effect of CE and DF was significantly weakened after the combined application of antibiotics, while the effect of TM on pain remained after the application of antibiotics. The expression of MyD88 in the articular cartilage was somewhat reduced by CE and DF. Additionally, the gas analysis showed a significant increase in the SCFA content in the feces of the drug-intervention group.
conclusionNSAID-induced changes in gut microbiota structure and the subsequent increase in SCFA production may contribute to their pain-alleviating effects in rats. Although to a lesser extent, NSAIDs can also slightly reduce localized inflammation in the joints.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.